{"id":"placebo-trastuzumab-docetaxel","safety":{"commonSideEffects":[{"rate":"40-60","effect":"Neutropenia"},{"rate":"30-50","effect":"Anemia"},{"rate":"30-40","effect":"Nausea/vomiting"},{"rate":"40-50","effect":"Fatigue"},{"rate":"20-30","effect":"Peripheral neuropathy"},{"rate":"5-10","effect":"Cardiotoxicity (trastuzumab-related)"},{"rate":"5-10","effect":"Hypersensitivity reactions"}]},"_chembl":null,"_fixedAt":"2026-03-30T12:49:08.113397","_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Trastuzumab is a monoclonal antibody that binds to HER2 receptors on cancer cells, preventing growth signaling and triggering immune-mediated cell death. Docetaxel is a taxane chemotherapy that stabilizes microtubules and prevents their disassembly, leading to mitotic arrest and apoptosis. Together they provide complementary mechanisms targeting HER2-positive cancers.","oneSentence":"This combination uses trastuzumab to block HER2 signaling in cancer cells while docetaxel disrupts microtubule dynamics to inhibit cell division, with placebo as a control arm.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:29:01.213Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"HER2-positive breast cancer (metastatic or early-stage)"},{"name":"HER2-positive gastric cancer"}]},"_fixedFields":["pubmed(4)"],"trialDetails":[{"nctId":"NCT04784715","phase":"PHASE3","title":"Trastuzumab Deruxtecan (T-DXd) With or Without Pertuzumab Versus Taxane, Trastuzumab and Pertuzumab in HER2-positive Metastatic Breast Cancer (DESTINY-Breast09)","status":"ACTIVE_NOT_RECRUITING","sponsor":"AstraZeneca","startDate":"2021-04-26","conditions":"Breast Cancer; HER2-positive; Metastatic","enrollment":1157},{"nctId":"NCT03199885","phase":"PHASE3","title":"Testing the Drug Atezolizumab or Placebo With Usual Therapy in First-Line HER2-Positive Metastatic Breast Cancer","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2019-04-05","conditions":"Metastatic Breast Adenocarcinoma, Metastatic HER2-Positive Breast Carcinoma, Recurrent Breast Adenocarcinoma","enrollment":190},{"nctId":"NCT01358877","phase":"PHASE3","title":"A Study of Pertuzumab in Addition to Chemotherapy and Trastuzumab as Adjuvant Therapy in Participants With Human Epidermal Growth Receptor 2 (HER2)-Positive Primary Breast Cancer","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2011-11-08","conditions":"Breast Cancer","enrollment":4804},{"nctId":"NCT03588091","phase":"PHASE3","title":"Neoadjuvant Study of Pyrotinib in Combination With Trastuzumab in Patients With HER2 Positive Breast Cancer","status":"COMPLETED","sponsor":"Jiangsu HengRui Medicine Co., Ltd.","startDate":"2018-07-24","conditions":"HER2-positive Breast Cancer","enrollment":355},{"nctId":"NCT01120184","phase":"PHASE3","title":"A Study of Trastuzumab Emtansine (T-DM1) Plus Pertuzumab/Pertuzumab Placebo Versus Trastuzumab [Herceptin] Plus a Taxane in Participants With Metastatic Breast Cancer (MARIANNE)","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2010-07-31","conditions":"Breast Cancer","enrollment":1095},{"nctId":"NCT02586025","phase":"PHASE3","title":"Study in Participants With Early-Stage or Locally Advanced Human Epidermal Growth Factor Receptor (HER) 2-Positive Breast Cancer to Evaluate Treatment With Trastuzumab Plus (+) Pertuzumab + Docetaxel Compared With Trastuzumab + Placebo + Docetaxel","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2016-03-14","conditions":"Breast Cancer","enrollment":329},{"nctId":"NCT05698186","phase":"PHASE3","title":"Thero2-01S22 in HER2-positive Breast Cancer","status":"NOT_YET_RECRUITING","sponsor":"Institut de cancérologie Strasbourg Europe","startDate":"2023-05-15","conditions":"HER2-positive Breast Cancer","enrollment":320},{"nctId":"NCT03863223","phase":"PHASE3","title":"A Study of Pyrotinib in Combination With Trastuzumab and Docetaxel in Patients With HER2 Metastatic Breast Cancer","status":"UNKNOWN","sponsor":"Jiangsu HengRui Medicine Co., Ltd.","startDate":"2019-04-22","conditions":"Metastatic Breast Cancer","enrollment":590},{"nctId":"NCT02896855","phase":"PHASE3","title":"A Study to Evaluate the Efficacy and Safety of Pertuzumab + Trastuzumab + Docetaxel Versus Placebo + Trastuzumab + Docetaxel in Previously Untreated Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Metastatic Breast Cancer","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2016-09-13","conditions":"Breast Cancer","enrollment":243},{"nctId":"NCT01220128","phase":"PHASE2","title":"Evaluation of an Anti-cancer Immunotherapy Combined With Standard Neoadjuvant Treatment in Patients With WT1-positive Primary Invasive Breast Cancer","status":"TERMINATED","sponsor":"GlaxoSmithKline","startDate":"2011-04-11","conditions":"Neoplasms, Breast","enrollment":66},{"nctId":"NCT00567190","phase":"PHASE3","title":"A Study to Evaluate Pertuzumab + Trastuzumab + Docetaxel vs. Placebo + Trastuzumab + Docetaxel in Previously Untreated HER2-Positive Metastatic Breast Cancer","status":"COMPLETED","sponsor":"Genentech, Inc.","startDate":"2008-02-12","conditions":"Metastatic Breast Cancer","enrollment":808},{"nctId":"NCT03811418","phase":"PHASE3","title":"A Study to Compare Pertuzumab + Trastuzumab + Vinorelbine vs. Placebo + Trastuzumab + Docetaxel in Previously Untreated HER2-positive Metastatic Breast Cancer","status":"WITHDRAWN","sponsor":"iOMEDICO AG","startDate":"2019-01","conditions":"Advanced Breast Cancer, HER2-positive Breast Cancer","enrollment":""},{"nctId":"NCT03756064","phase":"NA","title":"Neoadjuvant Study of Pyrotinib in Patients With HER2 Positive Breast Cancer","status":"UNKNOWN","sponsor":"Zhejiang Cancer Hospital","startDate":"2019-08-01","conditions":"Breast Cancer, Neoplasm, Breast, Breast Diseases","enrollment":100}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":4,"recentPublications":[],"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Placebo, Trastuzumab, Docetaxel","genericName":"Placebo, Trastuzumab, Docetaxel","companyName":"Jiangsu HengRui Medicine Co., Ltd.","companyId":"jiangsu-hengrui-medicine-co-ltd","modality":"Small molecule","firstApprovalDate":"","aiSummary":"This combination uses trastuzumab to block HER2 signaling in cancer cells while docetaxel disrupts microtubule dynamics to inhibit cell division, with placebo as a control arm. Used for HER2-positive breast cancer (metastatic or early-stage), HER2-positive gastric cancer.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}